CLONING OF THE SEROTONIN 5-HT1B AND 5-HT1D RECEPTORS

Information

  • Research Project
  • 3509258
  • ApplicationId
    3509258
  • Core Project Number
    R44NS027789
  • Full Project Number
    5R44NS027789-03
  • Serial Number
    27789
  • FOA Number
  • Sub Project Id
  • Project Start Date
    12/1/1990 - 34 years ago
  • Project End Date
    11/30/1992 - 32 years ago
  • Program Officer Name
  • Budget Start Date
    12/1/1991 - 33 years ago
  • Budget End Date
    11/30/1992 - 32 years ago
  • Fiscal Year
    1992
  • Support Year
    3
  • Suffix
  • Award Notice Date
    12/6/1991 - 33 years ago

CLONING OF THE SEROTONIN 5-HT1B AND 5-HT1D RECEPTORS

DESCRIPTION: (Adapted from applicant's abstract) Molecular cloning and heterologous expression of human neurotransmitter receptors provides a means to study these important targets of drug action in isolation. Transfected cell lines which express single human receptor subtypes provide excellent experimental model systems, free of the many closely related receptor subtypes which confuse the analysis of data in complex neural tissues. Heterologous expression systems can be used as living cell assay systems for the determination of receptor activation of inhibition. Since both drug efficacy and drug affinity play central roles in the actions of therapeutic agents, high-throughput functional screening assays for single human receptor subtypes will provide important new tools for drug development. The overall goal of this project is to develop a set of sensitive, high-throughput assay systems which measure the functional activation of cloned human G protein-coupled receptors in cultured mammalian cells. In Phase I of this project, the applicants have successfully developed a fluorescence assay for receptor-mediated adenylate cyclase inhibition in mammalian cells transfected with the human serotonin 5-HT (1A) receptor gene. In Phase II, they intend to complete the characterization of this system, to optimize the assay methods for use in high-throughput functional drug screening, and to diversify our program by transfecting into our cell lines other cloned human receptors which stimulate or inhibit adenylate cyclase activity.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R44
  • Administering IC
    NS
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    SYNAPTIC PHARMACEUTICAL CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    PARAMUS
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    07652
  • Organization District
    UNITED STATES